By July 31, 2026: Billing team must immediately update the pharmacy benefits management system and claims processing software to reflect all PDL changes. SPECIFIC ACTIONS: (1) Update formulary status for all affected medications listed in the policy across nine drug classes; (2) Configure system to require prior authorization for: Mounjaro, Ozempic tablet, Ticagrelor (generic Brilinta), Ebglyss, Nemluvio, Spinosad, Piperonyl butoxide/pyrethrins, Hadlima, Starjemza, Selarsdi, Taltz, Enoby (Prolia class), Xtrenbo (Xgeva class), and Emflaza tablet (DMD Corticosteroids); (3) Remove from PDL and deny coverage for all discontinued products: Proventil HFA, ProAir Digihaler, Zegalogue, Byetta, Bydureon BCise, Insulin aspart generic (Novolog), Insulin aspart/aspart protamine generic (Novolog 70/30), Qtern brand, Amitiza, Nix, Rid, Ulesfia, Siliq, and Lindane; (4) Move to non-preferred status: Ventolin HFA, Brilinta, Invokamet, Invokana, Dapagliflozin/saxagliptin, Movantik, Crotan, Pruradik, Adalimumab-adbm (all), Avtozma, Kevzara, Pyzchiva, Yesintek, Imuldosa, Ustekinumab-aauz, Otezla XR/XR initiation pack, Cosentyx, and all non-preferred Prolia/Xgeva biosimilars; (5) Update encounter forms and prior authorization templates used by clinical staff; (6) Notify providers in all departments of coverage changes. WHO: Billing team updates system; IT department implements software changes; clinical staff updates templates; practice leadership communicates with providers. WHERE: In pharmacy billing module, claims processing rules, formulary database, and all prior authorization workflows. CONSEQUENCES: Claims for non-covered discontinued medications will be denied; claims lacking required prior authorization will be denied; incorrect coding of preferred vs. non-preferred drugs will result in payment delays or denials.